A R T I C L E S
Scheme 3 a
Torizawa et al.
a Reagents and conditions: (i) (1) (EtOCO)2, NaOEt, (2) conc DCl, (3) Cu; (ii) (1) [13C3]-ethyl malonate, t-BuOK/BuOD, (2) Tet-Cl, K2CO3, (3) H2,
Pd/C; (iii) (1) LiAlD4, (2) PDC; (iv) (1)
[
13C2;15N]-NAc-glycine, Ac2O, AcONa, (2) MeOH, Et3N; (v) (1) (S,S)-Et-DuPhos-Rh, H2,
(2) 1N-HCl.
Phe and [ul-13C,15N]-Tyr were purchased from Cambridge Isotope
efficiently, using a hydroxyl benzoic acid derivative as key
intermediate, starting from various types of 13C-labeled acetone
and ethyl malonate.
Laboratories. Each unlabeled amino acid was added to the system to a
final concentration of 1 mM. All of the NMR samples were prepared
according to the previously published method.15,26,27 Each NMR sample
contained 0.5 mM calmodulin in 5 mM MES-d13 (Cambridge Isotope
Laboratories), ca. 10 mM bis-Tris-d19 (Cambridge Isotope Laboratories)
to adjust the pH to 6.5,28 5 mM CaCl2, 0.1 mM NaN3, and 10% D2O
or 100% D2O. The NMR measurements were performed on a Bruker
DRX600 spectrometer equipped with a CryoProbe at 37 °C.
From 3, 4H-pyran-4-one 4 was obtained by a modification
of reported procedure.17,18 Then, 4H-pyran-4-one 4 was sub-
jected to a condensation/aromatization reaction to give the key
intermediate 5.19 For the synthesis of Tyr 1a (Scheme 1), the
hydroxyl group of 5 was methylated, and the ester was reduced
by LiAlD4. The following oxidation by PDC yielded 6.20 Then,
6 was converted into the dehydrotyrosine derivative 7 by a
condensation with labeled Gly derivatives.21,22 Compound 7 was
subjected to hydrogenation in the presence of (S,S)-Et-DuPhos-
Rh, as a catalyst in MeOH,23 and then was deprotected to give
Tyr 1a.24
For the preparation of Phe 1b, it is possible to synthesize it
only by the deoxygenation of the hydroxyl group of the key
intermediate 5. Thus, a reductive deuteration of the hydroxyl
group of 5 was carried out, using our recently reported methods
to place a deuterium at the Hú position.16,25 Then, as in the
method for the synthesis of Tyr, 9 was converted into Phe 1b.
For the synthesis of Phe 2 labeled simultaneously with 13C
in the ú position and with deuterium in the δ and ꢀ positions,
[2-13C]acetone was used instead of [1,3-13C2]acetone.
1
The H-13C HSQC spectra29 and the constant time (ct) version30
for the aromatic resonances shown in Figure 2 were obtained using
the samples in 100% D2O. The other spectra were measured using the
samples in 10% D2O. The 1H-13C (ct) HSQC spectra shown in Figures
4 and 5 were acquired using coherence selection with sensitivity
enhancement.31-33 All of the HSQC measurements for aromatic
resonances, except for the ct version, were performed under the
following conditions: data size, 128 (t1) × 1024 (t2) complex points;
13
t
( C) ) 30.3 ms and t2max(1H) ) 128 ms; and spectral widths in
1max
ω1(13C) and ω2(1H) of 4200 and 8000 Hz, respectively. The carrier
frequencies of 13C and 1H were 126 and 4.7 ppm, respectively. In each
t1 increment, eight transients were accumulated, and the repetition delay
was 1.2 s. The data set was zero-filled to 256 (t1) × 2048 (t2) complex
points. The ct-HSQC spectrum for the aromatic resonances was obtained
under the same conditions, except that the t1 complex points were 70
and t1max(13C) ) 16.6 ms, as limited by the constant evolution period
of 17 ms. Compared to the ct-HSQC measurements for the aromatic
resonances, the altered parameters in those for the aliphatic resonances
were as follows: 256 (t1) complex points, t1max(13C) ) 20.7 ms, ct
evolution ) 26.6 ms, spectral width in 13C ) 12 000 Hz, carrier
frequency of 13C ) 48 ppm, and zero-filling to 512 (t1) complex points
Experimental Section
Calmodulin was synthesized by the E. coli cell-free system, which
we developed.13-15 For the synthesis, the amounts of the labeled Phe
and Tyr added were 1.32 and 0.37 mg, respectively. The [ul-13C,15N]-
(17) Riegel, E.; Zwilgmeyer, F. Organic Syntheses, Coll. Vol. II; Wiley: New
York, 1943; p 126.
(26) Ikura, M.; Marion, D.; Kay, L. E.; Shih, H.; Krinks, M.; Klee, C. B.; Bax,
A. Biochem. Pharmacol. 1990, 40, 153-160.
(18) Organic Syntheses with Isotopes, Part II; Interscience Publishers, Inc.: New
York, 1958; p 1388.
(27) Ikura, M.; Kay, L. E.; Bax, A. Biochemistry 1990, 29, 4659-4667.
(28) Kelly, A. E.; Ou, H. D.; Withers, R.; Dotsch, V. J. Am. Chem. Soc. 2002,
124, 12013-12019.
(19) Lang, M.; Lang-Fugmann, S.; Steglich, W. Organic Syntheses; Wiley: New
York, 2002; Coll. Vol. 78, pp 113-122.
(29) Bodenhausen, G.; Ruben, D. J. Chem. Phys. Lett. 1980, 69, 185-189.
(30) Vuister, G. W.; Bax, A. J. Magn. Reson. 1998, 98, 428-435.
(31) Palmer, A. G., III; Cavanagh, J.; Wright, P. E.; Rance, M. J. Magn. Reson.
1991, 93, 151-170.
(32) Kay, L. E.; Keifer, P.; Saarinen, T. J. Am. Chem. Soc. 1992, 114, 10663-
10665.
(33) Schleucher, J.; Schwendinger, M.; Sattler, M.; Schmidt, P.; Schedletzky,
O.; Glaser, S. J.; Sorensen, O. W.; Griesinger, C. J. Biomol. NMR 1994, 4,
301-306.
(20) Beyer, J.; Lang-Fugmann, S.; Mu¨hlbauer, A.; Steglich, W. Synthesis 1998,
1047-1051.
(21) Erlenmeyer, E. Justus Liebigs. Ann. Chem. 1893, 275, 1-20.
(22) Ojima, I.; Kato, K.; Fujita, M. J. Org. Chem. 1989, 54, 4511-4522.
(23) Burk, M.; Feaster, J.; Nugent, W.; Harlow, R. J. Am. Chem. Soc. 1993,
115, 10125-10138.
(24) Li, G.; Patel, D.; Hurby, V. Tetrahedron Lett. 1993, 34, 5393-5396.
(25) Viswanatha, V.; Hruby, V. J. J. Org. Chem. 1980, 45, 2010-2012.
9
12622 J. AM. CHEM. SOC. VOL. 127, NO. 36, 2005